Sequence information
DRAVP ID DRAVPc019
Name Interferon beta-1a
Sequence
Molecular Formula C908H1408N246O252S7
Condition/Disease COVID-19
Group Approved
Type Protein
Description Interferon beta-1a is a form of recombinant human interferon which could used for the treatment of COVID-19.
Active sequence/Structure
External Links
DrugBank Accession Number DB00060
Pubchem ID 46504899
CHEMBL ID CHEMBL1201562
UNII XRO4566Q4R
CAS 145258-61-3
Reference Not Available
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04732949 | Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 (SPRINTER) | Severe Acute Respiratory Syndrome Coronavirus 2 / Coronavirus Disease 2019 (COVID‑19) Treatment | Completed | Phase 3 | Synairgen Research Ltd. |
| NCT04315948 | Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy) | Infections, Coronavirus / Coronavirus Disease 2019 (COVID‑19) Treatment | Active, not recruiting | Phase 3 | Institut National de la Santé Et de la Recherche Médicale, France |
| NCT04350671 | Interferon Beta 1a in Hospitalized COVID-19 Patients (IB1aIC) | Coronavirus Disease 2019 (COVID‑19) Treatment | Unknown | Phase 4 | Shahid Beheshti University of Medical Sciences |
